Back
  1. Home
  2. Request Item
institution logo
If you're member of the institution,  you just have to login to download the file in restricted access. It is not necessary to request a print.

Request copy

Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study.
Dieras, Veronique; Wildiers, Hans; Jassem, Jacek et al.
2015 • In Breast, 24, p. 182-190

Document(s) requested
Trebananib (AMG386 plus weekly paclitaxel ....pdf

The desired document is not currently available on open access. Nevertheless you can request an offprint through the form below. If your request is accepted you will receive by e-mail a link allowing you access to the document for 5 days, 5 download attempts maximum.


Request form

Fields marked with ✱ are compulsory.

Back to the reference
Contact ORBi